

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

**RE-DESIGNATION OF DIRECTOR
AND
RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sirnaomics Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Xiaochang Dai (戴曉暢) (“**Dr. Dai**”) has been re-designated from a non-executive Director to an executive Director with effect from July 19, 2022 (“**Dr. Dai’s Re-designation**”). The Board has also received a letter of resignation from Mr. Jiajun Lai (賴嘉俊) (“**Mr. Lai**”) to resign as a non-executive Director with effect from August 31, 2022.

Re-designation of Director

The Board hereby announces that Dr. Dai has been re-designated from a non-executive Director to an executive Director with effect from July 19, 2022.

The biographical details of Dr. Dai are set out as follows:

Dr. Dai, aged 59, was appointed as a non-executive Director in December 2021. Following Dr. Dai’s Re-designation, he becomes an executive Director. Dr. Dai participates in the formulation of the general corporate business plans, strategies and major decisions of the Company through the Board. Dr. Dai is a member of the remuneration committee of the Company (the “**Remuneration Committee**”).

Dr. Dai currently serves as a professor at School of Chemical Science and Engineering, Yunnan University since 2000, the executive director of Value Measure Investments Limited since January 2011 and the executive director of Trinity Power Limited since March 2012, respectively. Dr. Dai also serves as a director of Shenzhen Yunda Technology Industry Co., Ltd. (深圳市雲大科技產業有限公司) since August 2001.

Prior to joining the Group, Dr. Dai served as the executive director, director of scientific advisory committee, director of postdoctoral workstation, chief scientist at Yunda Technology Co., Ltd. (雲大科技股份有限公司), a company used to be listed on Shanghai Stock Exchange (stock code: 600181) and delisted since June 1, 2007, from January 2000 to December 2001, the chairman and general manager of Dalian High-tech Biopharmaceutical Co., Ltd. (大連高新生物製藥有限公司) in 2001, the chairman of Yunnan Walvax Biopharmaceutical Co., Ltd. (雲南沃森生物製藥有限公司), the predecessor of Walvax Biotechnology Co., Ltd. (雲南沃森生物技術股份有限公司), a company listed on Shenzhen Stock Exchange (stock code: 300142) from 2002 to 2004, the managing director of Kunming Baker Norton Pharmaceutical Co., Ltd. (昆明貝克諾頓製藥有限公司) in 2005, and the president of Kunyao Group Co., Ltd. (昆藥集團股份有限公司), a company listed on Shanghai Stock Exchange (stock code: 600422), from September 2015 to December 2017.

Dr. Dai obtained a bachelor's degree in chemistry in School of Chemistry, Yunnan Normal University in the People's Republic of China (the "PRC") in July 1983, a master's degree in biochemistry in Shanghai Institute of Biochemistry, Chinese Academy of Sciences in the PRC in July 1988, and a doctoral degree in chemistry from The Scripps Research Institute in San Diego, California, the United States of America (the "U.S.") in September 1998, respectively. He also conducted postdoctoral research in the laboratory of John N. Ablelson, Division of Biology and Biological Engineering, California Institute of Technology in the U.S. from November 1998 to December 1999.

The Board considered and accepted the recommendation from the nomination committee of the Company to re-designate Dr. Dai as an executive Director, after reviewing his academic qualifications, working experience and contributions to the Board during his tenure as a non-executive Director.

As at the date of this announcement, Dr. Dai was deemed to be interested in an aggregate of 8,300,007 shares of the Company (the "Shares") and underlying Shares, within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The current service contract for Dr. Dai as a non-executive Director has been terminated upon Dr. Dai's Re-designation. Dr. Dai has entered into a new service contract (the "Service Contract") with the Company in relation to his appointment as an executive Director for a term of three years commencing from July 19, 2022, which may be terminated by not less than 3 months' notice in writing served by either party on the other and is subject to termination provisions therein and provisions on retirement by rotation of Directors as set out in the articles of association of the Company. Pursuant to the Service Contract, Dr. Dai is entitled to nil annual emolument. On July 19, 2022, Dr. Dai has also entered into an employment contract with Sirnaomics (Hong Kong) Limited, an indirect wholly-owned subsidiary of the Company, in relation to his appointment as a scientific and

strategic director. Dr. Dai is entitled to an annual emolument of US\$277,650 which is determined by the Board with reference to his background, qualifications, experience, level of responsibilities undertaken with the Group and prevailing market conditions. The emolument of Dr. Dai will be subject to annual review by the Remuneration Committee and the Board.

Save as disclosed above, as at the date of this announcement, Dr. Dai confirmed that (i) he has not held any directorship in other public listed companies in Hong Kong or overseas in the past three years; (ii) he does not hold any other position with the Company or subsidiaries of the Company; (iii) he does not have any other major appointments and professional qualifications; (iv) he does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (v) he does not hold any other interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of any other information relating to Dr. Dai's Re-designation that is required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and there are no other matters that need to be brought to the attention of the shareholders of the Company.

Resignation of non-executive Director

The Board announces that Mr. Lai has resigned as a non-executive Director with effect from August 31, 2022, as Mr. Lai wishes to devote more time to his other commitments. Mr. Lai has confirmed that he had no disagreement with the Board and there were no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Lai for his valuable contribution to the Company during his tenure of office.

By order of the Board
Sirnaomics Ltd.
Yang (Patrick) Lu
Chairman and Executive Director

Hong Kong, July 19, 2022

As at the date of this announcement, the Board comprises Dr. Yang Lu (alias Patrick Lu), Dr. Michael V. Molyneaux, Dr. David Mark Evans and Dr. Xiaochang Dai as executive Directors, Mr. Mincong Huang, Mr. Da Liu, Mr. Jiajun Lai and Mr. Jiankang Zhang as non-executive Directors, and Dr. Cheung Hoi Yu, Mr. Fengmao Hua, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law) as independent non-executive Directors.